Our CorplexTM technology platform enables the development of new transdermal therapeutics incorporating small molecule drugs previously thought to have been incapable of delivery through skin.
Today Corium scientists are not only envisioning – but are creating – products that address unmet patient needs, while improving compliance through simple, less frequent dosing regimens.
Corplex technology has been widely commercialized in our partner Procter & Gamble’s Crest® Whitestrips product line. The design of the Crest Whitestrips product is distinguished by reliable adhesion in both wet and dry environments, which is made possible by Corplex’s unique polymer combinations and compositions. Working with Corplex, Corium scientists are able to create a range of transdermal delivery profiles from immediate to sustained release, including the potential to create combinations of fast-acting and long-lasting release profiles.
Specific characteristics of Corplex include:
- Controlled and sustained delivery
- High drug load and efficient delivery;
- Adhesion to wet and dry surfaces;
- Flexible with skin movement;
- Ease of application and removal; and
- Non-irritating and non-sensitizing.
This technology has been successfully used to develop products in a variety of forms, including liquid (sprays, film formers), semisolid (gel, creams and ointment-like) or solid (powder, particles, dry and wet films, and patches).